- Home
- LUMO
LUMO
Lumos Pharma Inc.
as 07-26-2024 4:00pm EST
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as Lumos Pharma Inc. LUMO prepares to release earnings report on 01 Aug 2024.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 11.9M | IPO Year: | N/A |
| Target Price: | $18.00 | AVG Volume (30 days): | 42.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.37 - $4.55 | Next Earning Date: | 08-01-2024 |
| Revenue: | $1,525,000 | Revenue Growth: | -27.48% |
| Revenue Growth (this year): | 602.29% | Revenue Growth (next year): | -95.28% |
Stock Insider Trading Activity of Lumos Pharma Inc. (LUMO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McKew John C. | LUMO | Chief Scientific Officer | Apr 1 '24 | Sell | $2.78 | 2,214 | $6,143.85 | 17,153 | SEC Form 4 |
| McKew John C. | LUMO | Chief Scientific Officer | Feb 6 '24 | Sell | $3.03 | 438 | $1,328.02 | 18,403 | SEC Form 4 |
Latest Lumos Pharma Inc. News
LUMO Breaking Stock News: Dive into LUMO Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
GlobeNewswire
2 months ago
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
GlobeNewswire
2 months ago
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
GuruFocus.com
2 months ago
Lumos Pharma Inc (LUMO) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial ...
GlobeNewswire
2 months ago
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
GlobeNewswire
3 months ago
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
GlobeNewswire
3 months ago
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
GlobeNewswire
4 months ago
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
Compare LUMO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LUMO Lumos Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.